RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer

Exclusion Criteria

• •Currently participating in an interventional clinical investigational treatment, or have received other investigational drugs or treatment with an investigational device within 4 weeks prior to the first dose
• •Received anti-PD-1, anti-PD-L1, anti-CTLA-4, and other checkpoint inhibitor
• •Received traditional Chinese medicines or immunomodulatory drugs with anti-gastric cancer indications within 2 weeks before the first administration
• •Active autoimmune diseases or immunodeficiency diseases
• •Allergy to any test drug and its excipients, or a history of severe allergy, or contraindication to the test drug
• •Severe mental disorder
• •Receiving systemic corticosteroids within 7 days prior to the first dose of the study
• •Clinically apparent cardiovascular and cerebrovascular disease